INCIDENCE OF AUTOANTIBODIES IN PATIENTS WITH AUTOIMMUNE LIVER DISEASES AND CHRONIC HEPATITIS C

Abstract. Detection of circulating autoantibodies provides valuable diagnostic criteria for autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC). In this study, a panel of autoantibodies (ANA, ASMA, AMA) and ANCA was determined by indirect immunofluorescence assay in 191 patients, including those with AIH type 1 (n = 42), with PBC (n = 39), with overlapping AIH-1/PBC syndrome (n = 20), and 100 patients with viral hepatitis С (HCV). Autoantibodies against PDC/AMA-M2, M2-3E, PML, Sp100, gp210, SSA-Ro52, SLA/LP, LC-1 were detected by means of immune blotting in 53 patients with autoimmune liver diseases (AIH, 19; PBC, 23; AIH/PBC, 11). ANA were detected in 88.1% of AIH-1 patients, 89.7% of PBC cases, and 100% of combined AIH-1/PBC syndrome, with highest ANA titers observed in the latter group. In patients with HCV, ANA were detected in 20%, and ASMA in 2% of the cases.

ASMA and ANCA were found in monovariant AIH only (61.9% for ASMA, р < 0.001), and 35.7% for ANCA (р < 0.01). Anti-SLA/LP were detected in 15% of AIH patients, mostly with negative ANA and ASMA. PDC/AMA-M2 were identified in all patients with PBC and AIH-1/PBC, whereas AMA was detectable in 84.6% of PBC patients. Anti-M2-3E antibodies were found only in patients with PBC including those with an overlap syndrome. Occurence of detectable antibodies to gp210, Sp100, PML and SSA-Ro52 was similar in all groups. In our study, we have not confirmed a view that anti-gp210 and anti-Sp100 antibodies are highly specific for primary biliary cirrhosis.

1. Барановский А.Ю., Райхельсон К.Л., Мительглик У.А. Поздняя диагностика аутоиммунных заболеваний печени: причины и последствия // Экспериментальная и клиническая гастроэнтерология. – 2007. – № 8. – С. 36-42. Baranovskiy A.Yu., Raykhel`son K.L., Mitel`glik U.A. Pozdnyaya diagnostika autoimmunnykh zabolevaniy pecheni: prichiny i posledstviya [Late diagnosis of autoimmune liver diseases: causes and consequences]. Eksperimental`naya i klinicheskaya gastroenterologiya – Experimental and Clinical Gastroenterology, 2007, no. 8, pp. 36-42.

2. Дунаева Н.В., Неустроева Ю.А., Тихомирова Т.А., Сысоев К.А., Алексеева Н.П., Лапин С.В., Эсауленко Е.В., Добронравов В.А., Чухловин А.Б., Тотолян А.А. Распространенность и факторы риска развития криоглобулинемии, ассоциированной с хроническим гепатитом // Медицинская иммунология. – 2007. – Т. 9, № 6. – С. 575-580. Dunaeva N.V., Neustroeva Yu.A., Tikhomirova T.A., Sysoev K.A., Alekseeva N.P., Lapin S.V., Esaulenko E.V., Dobronravov V.A., Chukhlovin A.B., Totolian A.A. Rasprostranennost` i faktory riska razvitiya krioglobulinemii, assotsiirovannoy s khronicheskim gepatitom [Prevalence and risk factors in development of chronic hepatitis c-associated cryoglobulinemia]. Meditsinskaya immunologiya – Medical Immunology, 2007, vol. 9, no. 6, pp. 575-580.

3. Лапин C.В., Тотолян А.А. Иммунологическая лабораторная диагностика аутоиммунных заболеваний. – СПб.: Человек, 2010. – 272 с. Lapin S.V., Totolian A.A. Immunologicheskaya laboratornaya diagnostika autoimmunnykh zabolevaniy [Immunological laboratory diagnostics of autoimmune diseases]. St. Petersburg, Human, 2010. 272 p.

4. Лапин С.В., Тотолян А.А. Антинуклеарные антитела: лабораторные тесты и диагностическое значение // Медицинская иммунология. – 2001. – Т. 3, № 1. – С. 35-50. Lapin S.V., Totolian A.A. Antinuklearnye antitela: laboratornye testy i diagnosticheskoe znachenie [Antinuclear Antibodies: Laboratory Tests and Diagnostic Significance]. Meditsinskaya immunologiya – Medical Immunology, 2001, vol. 3, no. 1, pp. 35-50.

5. Широкова Е.Н., Ивашкин К.В., Григович М.А., Маевская М.В., Ивашкин В.Т. Клиническая характеристика перекрестного синдрома аутоиммунный гепатит / первичный билиарный цирроз // Российские медицинские вести – 2011. – Т. 16, № 4. – С. 40-47. Shirokova E.N., Ivashkin K.V., Grigovich M.A., Maevskaya M.V., Ivashkin V.T. Klinicheskaya kharakteristika perekrestnogo sindroma autoimmunnyy gepatit/pervichnyy biliarnyy tsirroz [The clinical characteristic of overlap syndrome autoimmune hepatitis / primary biliary cirrhosis]. Rossiyskie meditsinskie vesti – Russian medical news, 2011, vol. 16, no. 4, pp. 40-47.

6. Abuaf N., Johanet C., Chretien P., Martini E., Soulier E., Laperche S., Homberg J.C. Characterization of liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. J. Hepatol., 1992, vol. 16, pp. 892-898.

7. Agarwal N., Handa R., Acharya S.K., Wali J.P., Dinda A.K., Aggarwal P. A study of autoimmune markers in hepatitis C infection. J. Indian. Med. Res. 2001, vol. 113, рр.170-174.

8. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol., 1999, vol. 31, рр.929-938.

9. Baeres M., Herkel J., Czaja A.J., Wies I., Kanzler S., Cancado E.L., Porta G., Nishioka M., Simon T., Daehnrich C., Schlumberger W., Galle P.R., Lohse A.W. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut., 2002, vol. 51, pp. 259-264.

10. Ballot E., Homberg J.C., Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 autoimmune hepatitis. J. Hepatol., 2000, vol. 33, рр. 208-215.

11. Boberg K.M., Chapman R.W., Hirschfield G.M., Lohse A.W., Manns M.P., Schrumpf E. on behalf of the International Autoimmune Hepatitis Group. Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J. Hepatol., 2011, vol. 54, no. 2, рр. 374-385.

12. Chazouilleres O., Wendum D., Serfaty L., Montembault S., Rosmorduc O., Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. J. Hepatol., 1998, vol. 28, рр. 296-301.

13. Clifford B.D., Donahue D., Smith L., Cable E., Luttig B., Manns M., Bonkovsky H.L. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. J. Hepatol., 1995, vol. 21, pp. 613-619.

14. Czaja A.J. Autoimmune liver disease. J. Curr. Opin. Gastroenterol., 2002, vol. 18, рр. 334-344.

15. Czaja A.J., Cassani F., Cataleta M. Antinuclear antibodies and patterns of nuclear immunoflorescence in type 1 autoimmune hepatitis. J. Dig. Dis. Sci., 1997, vol. 42, рр. 1688-1696.

16. Czaja A.J., Shums Z., Norman G.L. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. J. Autoimmunity., 2002, vol. 35, no. 18, pp. 475-483.

17. Dalekos G.N., Zachou K., Liaskos C., Gatselis N. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. J. Intern. Med., 2002, vol. 13, рр. 293-303.

18. EASL Clinical Practice Guidelines. Management of cholestatic liver diseases. J. Hepatol., 2009, Vоl. 51, рр. 237-267.

19. Gleeson D., Heneghan M.A. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. J. Gut, 2011, vol. 60, рр. 1611-1629.

20. Granito A., Muratori P., Muratori L., Pappas G, Cassani F, Worthington J, Guidi M., Ferri S, De Molo C, Lenzi M., Chapman R.W., Bianchi F.B. Antinuclear antibodies giving the ‘multiple nuclear dots’ or the ‘rim-like/ membranous’ patterns: diagnostic accuracy for primary biliary cirrhosis. J. Aliment. Pharmacol. Ther., 2006, vol. 24, рр. 1575-1583.

21. Hennes E.M., Zeniya M., Czaja A.J., Hennes E.M., Zeniya M., Czaja A.J., Par s A., Dalekos G.N., Krawitt E.L., Bittencourt P.L., Porta G., Boberg K.M., Hofer H., Bianchi F.B., Shibata M., Schramm C., Eisenmann de Torres B., Galle P.R., McFarlane I., Dienes H.P., Lohse A.W. International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. J. Hepatol., 2008, vol. 48, рр. 169-176.

22. Invernizzi P., Selmi C., Ranftler C., Podda M., Wesierska-Gadek J. Anti nuclear antibodies in primary biliary cirrhosis. J. Semin. Liver Dis., 2005, vol. 25, рр. 298-310.

23. Kanzler S., Weidemann C., Gerken G., Lohr H.F., Galle P.R., Meyer zum Buschenfelde K.H., Lohse A.W. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J. Hepatol.,1999, vol. 31, рр. 635-640.

24. Krawitt E.L. Autoimmune hepatitis. J. Med. N. Engl, 2006, vol. 354, рр. 54-66.

25. Lenzi M., Bellentani S., Saccoccio G., Muratori P., Masutti F., Muratori L., Cassani F., Bianchi F.B., Tiribelli C. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. J. Gut, 1999, vol. 45, pp. 435-441.

26. Lindor K.D., Gershwin M.E., Poupon R., Kaplan M., Bergasa N.V., Heathcote E.J. Primary biliary cirrhosis. AASLD practice guidelines. J. Нepatol., 2009, vol. 50, рр. 291-308.

27. Manns M.P., Czaja A.J., Gorham J.D., Manns M.P., Czaja A.J., Gorham J.D., Krawitt E.L., Mieli-Vergani G., Vergani D., Vierling J.M. Diagnosis and Management of Autoimmune Hepatitis. J. Hepatol., 2010, vol. 51, рр. 2193-2213.

28. Martini E., Abuaf N., Cavalli F., Durand V., Johanet C., Homberg J.C. Antibody to liver cytosol (anti-LC1) in patients with autoimmune hepatitis type 2. J. Hepatol., 1988., vol. 8., рр. 1662-1666.

29. Milkiewicz P., Buwaneswaran H., Coltescu C., Shums Z., Norman G.L., Heathcote E.J. Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease. J. Clin. Gastroenterol. Hepatol., 2009, vol. 7, рр. 1355-1360.

30. Monti V., Aghemo A., Rumi M.G., Donato M.F., Del Ninno E., Colombo M. The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liverkidney microsome type 1 antibodies. J. Antivir. Ther., 2005, vol. 10, рр. 715-720.

31. Muratori P., Muratori L., Guidi M., Granito A., Susca M., Lenzi M., Bianchi F.B. Clinical impact of nonorganspecific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. J. Clin. Infect. Dis., 2005, vol. 40, рр. 501-507.

32. Muratori L., Granito A., Muratori P. Pappas G., Bianchi F.B. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. J. Clin. Liver. Dis., 2008, vol. 12, рр. 261-276.

33. Muratori P., Granito A., Pappas G., Muratori L., Lenzi M., Bianchi F.B. Autoimmune liver disease 2007. J. Mol. Aspects Med., 2008, vol. 29, рр. 96-102.

34. Parveen S., Morshed S.A., Arima K., Parveen S., Morshed S.A., Arima K., Nishioka M., Czaja A.J., Chow W.C., Ng H.S. Antibodies to Ro/La, Cent-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association. J. Dig. Dis. Sci., 1998, vol. 43, рр. 1322-1331.

35. Roozendaal C., de Jong M.A., van den Berg A.P., van Wijk R.T., Limburg P.C, Kallenberg C.G.M. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J. Hepatol., 2000, vol. 32, рр. 734-741.

36. Strassburg C.P., Manns M.P. Autoantibodies and autoantigens in autoimmune hepatitis. J. Semin. Liver Dis., 2002, vol. 22, рр. 339-352.

37. Szostecki C., Krippner H., Penner E., Szostecki C., Krippner H., Penner E., Bautz F.A. Autoimmune sera recognize a 100-kD nuclear protein antigen (sp-100). J. Clin. Exp. Immunol., 1987, vol. 68, рр. 108-116.

38. Talwalkar J.A., Lindor K.D. Primary biliary cirrhosis. J. Lancet., 2003, vol. 5, рр. 53-61.

39. Targan S.R., Landers C., Vidrich A., Czaja A.J. High titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. J. Gastroenterol., 1995, vol. 108, рр. 1159-1166.

40. Treichel U., McFarlane B.M., Seki T., Krawitt E.L., Alessi N., Stickel F., McFarlane I.G., Kiyosawa K., Furuta S., Freni M.A. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. J. Gastroenterol., 1994, vol. 107, рр. 799-804.

41. Worman H.J., Courvalin J.C. Antinuclear antibodies specific for primary biliary cirrhosis. J. Autoimmun Rev., 2003, vol. 2, рр. 211-217.

42. Yee L.J., Kelleher P., Goldin R.D., Marshall S., Thomas H.C., Alberti A., Chiaramonte M., Braconier J.H., Hall A.J., Thursz M.R. Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. J. Viral. Hepat., 2004, vol. 11, рр. 459-464.

43. Zuchner D., Sternsdorf T., Szostecki C., Z chner D., Sternsdorf T., Szostecki C., Heathcote E.J., Cauch-Dudek K., Will H. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. J. Hepatol., 1997, vol. 26, рр. 1123-1130.